, Volume 46, Issue 2, pp 173–178 | Cite as

Urinary stone disease in pediatric and adult metabolic bone clinic patients

  • Andrew L. Schwaderer
  • Abimbola Oduguwa
  • Kirsten Kusumi
Original Paper


Kidney stones are increasing in the pediatric and adult populations; similarly osteoporosis is increasingly recognized in children. While kidney stone formers are known to suffer from low bone density, metabolic bone patients have not been considered a high risk population for kidney stones. Retrospective chart review of Nationwide Children’s Hospital Metabolic Bone Clinic patients from October 2009–2013. Patients were identified by ICD 9 codes for osteoporosis, osteopenia, low bone density and kidney stones. Only patients with radiologic evidence of both diseases were included.Twenty-six of 889 patients met criteria; this is equivalent to an incidence of 30 per 100,000 patients. Osteoporosis was the most frequent bone diagnosis. Males were the majority (68%). Most common secondary diagnoses: seizure (52%) and cerebral palsy (44%). Treatment: calcium (48%), vitamin D (40%), bisphosphonates (48%). The majority (75%) were non-ambulatory. Most frequent lithogenic medications: Topiramate (42%) and corticosteroids (27%). This is one of the first studies to consider metabolic bone patients as high risk for urinary stone disease. We found a higher rate of kidney stones in pediatric metabolic bone patients compared to data available for the general pediatric kidney stone population. The most common risk factor for bone and stone disease was nonambulatory status. Males were more frequently affected than females; this is the reverse of general adolescent kidney stone population. The predominance of cerebral palsy and seizure patients can be attributed to their frequency of non-ambulatory status and lithogenic medications such as Topiramate.


Urolithiasis 1 Bone mineral density 2 Special populations 3 Pediatric 4 


Compliance with ethical standards

The authors did not receive any funding for this project.

Dr. Schwaderer declares that he has no conflict of interest. Dr. Odugawa declares that she has no conflict of interest. Dr. Kusumi declares that she has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Our study was approved by the Nationwide Children’s Hospital IRB. This study was a retrospective chart review, thus we did not obtain consent from our subjects. This was approved by the Nationwide Children’s Hospital IRB.


  1. 1.
    Alon US, Zimmerman H, Alon M (2004) Evaluation and treatment of pediatric idiopathic urolithiasis-revisited. Pediatr Nephrol 19:516–520CrossRefPubMedGoogle Scholar
  2. 2.
    Cameron MA, Sakhaee K, Moe OW (2005) Nephrolithiasis in children. Pediatr Nephrol 20:1587–1592CrossRefPubMedGoogle Scholar
  3. 3.
    Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB (2000) Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 13:169–177PubMedGoogle Scholar
  4. 4.
    Curtiss PH Jr, Clark WS, Herndon CH (1954) Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. J Am Med Assoc 156:467–469CrossRefPubMedGoogle Scholar
  5. 5.
    Denburg MR, Leonard MB, Haynes K, Tuchman S, Tasian G, Shults J, Copelovitch L (2014) Risk of fracture in urolithiasis: a population-based cohort study using the health improvement network. Clin J Am Soc Nephrol CJASN 9: 2133–2140CrossRefPubMedGoogle Scholar
  6. 6.
    Hufnagle KG, Khan SN, Penn D, Cacciarelli A, Williams P (1982) Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 70:360–363PubMedGoogle Scholar
  7. 7.
    Hyams JS (1994) Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 19: 7–21CrossRefPubMedGoogle Scholar
  8. 8.
    Jorgensen L, Jacobsen BK, Wilsgaard T, Magnus JH (2000) Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 11: 381–387Google Scholar
  9. 9.
    Kaplon DM, Penniston KL, Nakada SY (2011) Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate. Urology 77:295–298CrossRefPubMedGoogle Scholar
  10. 10.
    Khan SR (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8:75–88CrossRefPubMedGoogle Scholar
  11. 11.
    Koyun M, Güven AG, Filiz S, Akman S, Akbas H, Baysal YE, Dedeoglu N (2007) Screening for hypercalciuria in schoolchildren: what should be the criteria for diagnosis? Pediatr Nephrol 22:1297–1301CrossRefPubMedGoogle Scholar
  12. 12.
    Kusumi K, Becknell B, Schwaderer A (2014) Trends in pediatric urolithiasis: patient characteristics, associated diagnoses, and financial burden Pediatr NephrolGoogle Scholar
  13. 13.
    Lauderdale DS, Thisted RA, Wen M, Favus MJ (2001) Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res Offi J Am Soc Bone Miner Res 16: 1893–1898CrossRefGoogle Scholar
  14. 14.
    Ma NS, Gordon CM (2012) Pediatric osteoporosis: where are we now? J Pediatr 161:983–990CrossRefPubMedGoogle Scholar
  15. 15.
    Miller LA, Stapleton FB (1985) Urinary citrate excretion in children with hypercalciuria. J Pediatr 107:263–266CrossRefPubMedGoogle Scholar
  16. 16.
    Schwaderer AL, Cronin R, Mahan JD, Bates CM (2008) Low bone density in children with hypercalciuria and/or nephrolithiasis. Pediatr Nephrol 23:2209–2214CrossRefPubMedGoogle Scholar
  17. 17.
    Sela J, Applebaum J, Uretzky G (1986) Osteogenesis induced by bone matrix is inhibited by inflammation. Biomater Med Devices Artif Organs 14:227–237CrossRefPubMedGoogle Scholar
  18. 18.
    Tanaka Y, Nakayamada S, Okada Y (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4:325–328CrossRefPubMedGoogle Scholar
  19. 19.
    Tsao KC, Wu TL, Chang PY, Sun CF, Wu LL, Wu JT (2007) Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones. J Clin Lab Anal 21:426–431CrossRefPubMedGoogle Scholar
  20. 20.
    van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMedGoogle Scholar
  21. 21.
    Welten DC, Kemper HC, Post GB, Van Mechelen W, Twisk J, Lips P, Teule GJ (1994) Weight-bearing activity during youth is a more important factor for peak bone mass than calcium intake. J Bone Miner Res Off J Am Soc Bone Miner Res 9: 1089–1096CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Division of Nephrology, Department of Pediatrics, Nationwide Children’s HospitalThe Ohio State UniversityColumbusUSA
  2. 2.Division of NephrologyAkron Children’s HospitalAkronUSA

Personalised recommendations